Literature DB >> 10233318

The extent and nature of disability in different urticarial conditions.

E Poon1, P T Seed, M W Greaves, A Kobza-Black.   

Abstract

Chronic forms of urticaria are common, often adversely impacting on quality of life. No formal studies have assessed the extent and nature of disability in different types of urticaria. The Dermatology Life Quality Index (DLQI) is a simple and validated 10-item questionnaire designed to measure and compare disability in different skin conditions. In this study, we aimed to assess the disability in different urticarial groups using the DLQI, allowing comparison with previously published DLQI scores in common skin diseases. The DLQI was administered to 170 consecutive patients attending a specialist urticaria clinic over a 4-month period. Consistent with previous studies using the DLQI, mean scores were not influenced by gender or age. Patients with chronic idiopathic urticaria without a concurrent physical urticaria (n = 47) suffered moderate quality of life impairment (mean +/- SD DLQI 25 +/- 24%). In comparison, patients with chronic idiopathic urticaria with concurrent delayed pressure urticaria (DPU) (n = 26) suffered significantly higher quality of life impairment (mean +/- SD DLQI 43 +/- 23%, 95% confidence interval for difference 7-29%). Disability in this group was greatest in the dimensions of work/study, symptoms/feelings and leisure. Subjects with another form of physical urticaria, cholinergic urticaria, also endured high levels of disability (n = 9, mean +/- SD DLQI 50 +/- 34%). From our urticaria study group, we have shown that subjects with DPU and cholinergic urticaria endure the most quality of life impairment. The mean DLQI scores demonstrated in these groups are comparable with those previously seen in severe atopic dermatitis out-patients (60%) and higher than those seen in out-patients with psoriasis (29.7%), acne (24.3%) and vitiligo (16.1%).

Entities:  

Mesh:

Year:  1999        PMID: 10233318     DOI: 10.1046/j.1365-2133.1999.02767.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  32 in total

1.  [Physical urticaria].

Authors:  M Fleischer; J Grabbe
Journal:  Hautarzt       Date:  2004-04       Impact factor: 0.751

2.  Patients' perception of the value of levocetirizine in allergic diseases : a multicentre observational study in Germany.

Authors:  L Klimek; H Wrede; B C Schott; I Hansen
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

3.  Retrospective analysis of the efficacy of omalizumab in chronic refractory urticaria.

Authors:  Ravi K Viswanathan; Mark H Moss; Sameer K Mathur
Journal:  Allergy Asthma Proc       Date:  2013 Sep-Oct       Impact factor: 2.587

4.  The impact of chronic idiopathic urticaria on quality of life in korean patients.

Authors:  Min Ju Kang; Hei Sung Kim; Hyung Ok Kim; Young Min Park
Journal:  Ann Dermatol       Date:  2009-08-31       Impact factor: 1.444

5.  Validation of an Egyptian Arabic Version of Skindex-16 and Quality of Life Measurement in Egyptian Patients with Skin Disease.

Authors:  Nagwa Essa; Sara Awad; Mariam Nashaat
Journal:  Int J Behav Med       Date:  2018-04

6.  [Chronic urticaria. Prevalence, course, prognostic factors and impact].

Authors:  K Weller; S Altrichter; E Ardelean; K Krause; M Magerl; M Metz; F Siebenhaar; M Maurer
Journal:  Hautarzt       Date:  2010-09       Impact factor: 0.751

7.  The impact of lupus erythematosus cutaneous on the Quality of life: the Brazilian-Portuguese version of DLQI.

Authors:  L B Ferraz; F A Almeida; M R Vasconcellos; A S Faccina; R M Ciconelli; M B Ferraz
Journal:  Qual Life Res       Date:  2006-04       Impact factor: 4.147

Review 8.  New concepts of hive formation in cholinergic urticaria.

Authors:  Tastuya Horikawa; Atsushi Fukunaga; Chikako Nishigori
Journal:  Curr Allergy Asthma Rep       Date:  2009-07       Impact factor: 4.806

Review 9.  Urticaria and quality of life.

Authors:  Jean-Jacques Grob; Caroline Gaudy-Marqueste
Journal:  Clin Rev Allergy Immunol       Date:  2006-02       Impact factor: 8.667

10.  Impact of Desloratadine on Symptoms and Quality of Life in Subjects with Chronic Idiopathic Urticaria: A Multicenter, Practice-based Study.

Authors:  Harold Kim; Charles Lynde
Journal:  Arch Drug Inf       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.